Medicus Pharma

Medicus Pharma Current Assets

The Current Assets of Medicus Pharma (MDCX) as of Oct 28, 2026 is 9.89 M USD. In the previous year, Current Assets was 5.38 M USD — a change of 83.90% (higher).

Current Assets

9.89 MUSD

YoY

83.90%

Last updated:

Current Assets of Medicus Pharma is 2025 9.89 M USD. Current Assets of Medicus Pharma was 2024 5.38 M USD. It decreases by 83.90% higher compared to the previous year.

The Medicus Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
86,300.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
81,700.00 USD
Jan 1, 2021
78,514.00 USD
Jan 1, 2022
282,652.00 USD
Jan 1, 2023
1.89 M USD
Jan 1, 2024
5.38 M USD
Jan 1, 2025
9.89 M USD
The Medicus Pharma Current Assets history
YEARCurrent AssetsYoY
9.89 MUSD+83.90%
5.38 MUSD+184.11%
1.89 MUSD+569.75%
282,652.00USD+260.00%
78,514.00USD-3.90%
81,700.00USD—
0.00USD-100.00%
86,300.00USD—
0.00USD—
0.00USD—
0.00USD-100.00%
50,600.00USD-19.30%
62,700.00USD-27.93%
87,000.00USD-14.45%
101,700.00USD-91.22%
1.16 MUSD+166.99%
433,700.00USD+290.02%
111,200.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medicus Pharma Stock analysis

What does Medicus Pharma do? Medicus Pharma Ltd generates revenue through its clinical stage, multi-strategy holding company model, focusing on FDA-approved clinical trials. The company identifies, acquires, and advances de-risked clinical stage assets, including its subsidiary SkinJect, Inc., which develops a drug delivery system using dissolvable microneedle arrays for treating basal cell and squamous cell carcinoma. SkinJect targets non-melanoma skin cancer treatments, leveraging minimally invasive technology for commercialization. The firm's primary buyers are pharmaceutical and biotechnology companies seeking to expand their drug development pipelines through strategic acquisitions and partnerships. Medicus Pharma Ltd's subsidiary SkinJect, Inc. is positioned to attract industry partners interested in novel, minimally invasive treatments for skin cancer, aligning with the growing demand for targeted therapies in dermatology. The company's focus on FDA-approved clinical trials ensures regulatory compliance, making its assets attractive for potential commercialization partners. Medicus Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medicus Pharma stock

Current Assets of Medicus Pharma is 9.89 M USD in 2025.

Current Assets of Medicus Pharma changed from 5.38 M USD to 9.89 M USD, representing a 83.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Medicus Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Medicus Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medicus Pharma

All Key Metrics — Medicus Pharma